drugset / Trial / NCT07330440
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
RandomizedParallel-groupDouble-blindPrevention
Summary
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
Timeline
- Start
- 2025-10-13
- Primary completion
- 2027-03-04
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSV-2 mRNA Vaccine | Messenger RNA (mRNA) | 0.25 ml | — |
| Subject | HSV-2 mRNA Vaccine | Messenger RNA (mRNA) | 0.5 ml | — |
| Subject | HSV-2 mRNA Vaccine | Messenger RNA (mRNA) | 1 ml | — |